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Abstract
Background: The use of prescription drugs to improve cognitive functioning in normal persons –‘‘neuroenhancement’’ –
has gained recent attention from bioethicists and neuroscientists. Enthusiasts claim that the practice is widespread and
increasing, and has many potential benefits; however recent evidence provides weak support for these claims. In this study
we explored how the newsprint media portrays neuroenhancement.
Aims: We conducted an empirical study of media reporting of neuroenhancement to explore: media portrayals of the
prevalence of neuroenhancement; the types of evidence used by the media to support claims about its prevalence; and, the
possible benefits and risks of neuroenhancement mentioned in these media articles.
Methods: Using the Factiva database, we found 142 newspaper articles about the non-medical use prescription drugs for
neuroenhancement for the period 2008-2010. We conducted a thematic content analysis of how articles portrayed the
prevalence of neuroenhancement; what type of evidence they used in support; and, the potential benefits and risks/side-
effects of neuroenhancement that were mentioned.
Results: 87% of media articles mentioned the prevalence of neuroenhancement, and 94% portrayed it as common,
increasing or both. 66% referred to the academic literature to support these claims and 44% either named an author or a
journal. 95% of articles mentioned at least one possible benefit of using prescription drugs for neuroenhancement, but only
58% mentioned any risks/side effects. 15% questioned the evidence for efficacy of prescription drugs to produce benefits to
users.
Conclusions: News media articles mentioned the possible benefits of using drugs for neuroenhancement more than the
potential risks/side effects, and the main source for media claims that neuroenhancement is common and increasingly
widespread has been reports from the academic literature that provide weak support for this claim. We urge journalists and
researchers to be cautious in their portrayal of the non-medical use of drugs for neuroenhancement.
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Introduction
Overly enthusiastic media coverage of applications of neurosci-
ence research can unrealistically raise public expectations about
their future impact for good and ill [1,2]. Researchers have
expressed concerns that media reporting often misconstrues the
scope, feasibility, benefits and risks of new neurotechnologies. For
example, analyses of news reports of fMRI, Deep Brain
Stimulation, and neurosurgery suggest that their coverage has
exaggerated their efficacy in ways that may profoundly impact
public understanding [2]. The media has been similarly accused of
perpetuating ‘‘genohype’’ by inflating the benefits (and downplay-
ing the risks) of genetic research [3].
The source of media exaggeration can be researchers
themselves. In their examination of how the media reports the
neuroscience research on Attention Deficit Hyperactivity Disorder
(ADHD), Gonon and colleagues [4] found that the media often
accurately reported researchers’ optimistic extrapolations of
preliminary data to ‘‘therapeutic prospects’’, and researchers
reported stronger conclusions than their results warranted.
Because misleading media accounts may undermine responsible
public debate it is important to understand how the media
portrays scientific neuroscience research and innovation [5].
The potential use of drugs to enhance cognition: ‘‘smart
drugs’’
New insights into behaviour, cognition, and mental illness
afforded by the ‘‘neuroscience revolution’’ have increased public
interest in novel applications of this research, such as the use of
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neuroscience research, for example, has raised the possibility that
some prescription drugs used to treat ADHD, narcolepsy and
Alzheimer’s disease, may improve cognitive functions in healthy
people, such as executive function, alertness, concentration and
memory. This use of these drugs has been called ‘‘neuroenhance-
ment’’, or ‘‘cognitive enhancement’’. The most commonly
purportedly neuroenhancers [6] include modafinil (Provigil or
Nuvigil) which is indicated for the treatment of narcolepsy;
psychostimulants that are used to treat ADHD, such as
methylphenidate (Ritalin), or mixed amphetamine salts including
dextroamphetamine (Adderall); and drugs such as donepezil that
are used to treat Alzheimer’s Disease [7].
In a recent study of the print media’s portrayal of the non-
medical use of methylphenidate, Forlini and Racine [8] found
enthusiasm for the use of methylphenidate as a neuroenhancer.
The drug was often described in sensationalist terms as ‘‘brain
steroids’’, and ‘‘smart pills’’. News articles also exaggerated the
prevalence of neuroenhancement by describing it as widespread,
running the risk of normalizing such use and encouraging others to
engage in it. For example, a recent study of deaths from
unintentional prescription opioid poisonings found that media
articles about the nonmedical use of these drugs often preceded
increases in overdose deaths [9]. Some countries have developed
guidelines that promote the responsible media coverage of drug-
related material in an attempt to limit the unintended indirect
encouragement of nonmedical drug use (e.g. The Australian Press
Council [10]). However, these guidelines focus on reporting illicit
drug use rather than the enhancement use of prescription drugs.
Forlini and Racine [8] also found that the bioethics discourse on
the enhancement use of methylphenidate exhibited the same
enthusiasm displayed by the media. Several recent high profile
articles by bioethicists and neuroscientists in leading science
journals have argued that the neuroenhancement use of stimulant
drugs has much to offer healthy individuals and society (e.g. [11]).
They have also claimed that the enhancement use of these
prescription drugs is common and increasingly prevalent,
particularly among healthy university students (e.g. [6,11,12,13]).
Chatterjee [12], for example, has said that ‘‘based on the belief that
these drugs improve test performance, the use of stimulant medications among
college students in the US is widespread’’. Another bioethics article
reflecting this sentiment [6] prompted the journal Nature to
conduct an on line poll of its readers about their use of prescription
drugs for neuroenhancement – 20% of the 1400 self-selected
readers who responded to the survey reported that they had used
these drugs to improve their concentration [14]. Some articles
have also advocated policies and professional guidelines to
facilitate the practice [7] and ‘‘help society accept the benefits of
enhancement, given appropriate research and evolved regulation’’ [11].
However, other researchers have urged more caution about the
use of pharmaceutical drugs for neuroenhancement [15,16,17].
They have argued that the evidence for the effectiveness of such
drugs in healthy people is questionable and that the risks of
addiction and other long term dangers have not been well studied.
They point out those who claim that neuroenhancement is
widespread have often mistakenly equated all non-medical use of
stimulants with neuroenhancement, highlighted atypically high
prevalence estimates, and inflated estimated use by reporting
‘‘lifetime use’’ of stimulants rather than ‘‘past year’’ or ‘‘past
month’’ use (for a more comprehensive discussion of this, see [17]).
A recent review of 25 surveys of the prevalence of ‘‘smart drugs’’
usage found large variations in sample size, scope and ways in
which participants were asked about how and why they used
prescription stimulants non-medically [18]. These variations
severely limit the conclusions that can be drawn. Larger, more
representative studies typically report a past year prevalence of
nonmedical stimulant of between 3–6%. Surveys that reported the
highest prevalence rates tended to have smaller samples drawn
from single institutions. The enhancement use of Ritalin and
Adderall among US college students has also been uncritically
claimed to be globally representative of college students [11].
However, a recent survey of German university students and
pupils’ use of prescription stimulants for neuroenhancement found
that only 0.26% reported doing so in the past year [19].
Forlini and Racine [8] also noted that the enthusiasm shown in
both the media and bioethics discourse was supported by very
weak evidence of effectiveness (see also [20]). Several recent studies
have found that the neuroenhancing effects of a number of
prescription drugs in normal persons are equivocal at best [18]
and systematic reviews have found that enthusiasm for the
neuroenhancement use of anti-dementia drugs, methylphenidate,
and modafinil ‘‘exceeded their actual effects’’ [21,22].
The current study
We updated and extended Forlini and Racine’s analysis of 20
newspaper articles about the non-medical use of methylphenidate
from the period 2000–2006 [8] to take account of the publication
of a number of high-profile, often-cited articles published in high
impact journals since 2007 (for example [6,11,14]). We accord-
ingly conducted an empirical study of media reporting of cognitive
enhancement for the period 2008–2010. Newsprint articles that
discussed the use of prescription drugs (Ritalin, Adderall and
modafinil) specifically for neuroenhancement purposes (rather
than other non-medical uses such as recreation) were analysed. In
particular, we explored: media portrayals of the prevalence of
neuroenhancement; the types of evidence used by the media to
support claims about the prevalence of neuroenhancement; and,
the possible benefits and risks of neuroenhancement mentioned in
these media articles.
Methods
Search strategy
We conducted a search of print newspaper articles about
neuroenhancement listed in the Factiva database in English-
speaking sources between 1
st January 2008 and 31
st December
2010. Factiva is widely used for comprehensive newspaper article
searching and offers comparable coverage to other news service
databases (e.g. Lexis-Nexis). We chose newspapers because they are
the most widely circulated form of print media and they cater to a
broad, lay readership. Our sample was generated using a number
of iterative keyword searches that expanded on the search terms
used by Forlini and Racine [8] by including many of the terms that
their study identified in media reporting of neuroenhancement
(e.g. ‘‘smart drug’’, methylphenidate, Ritalin, cognitive enhance-
ment). The search also included key terms used in the academic
literature such as ‘‘cosmetic neurology’’ or ‘‘brain doping’’ and the
names of drugs that are referred to as potential neuroenhancers,
including their brand names (e.g. Ritalin, Provigil, Adderall). The
final search strategy was:
neuroenhance* OR neuro-enhance* OR nootropic* OR
cosmetic neurology OR cosmetic psychopharmacology
OR
(Ritalin OR methylphenidate OR modafinil or Adderall or
dexamphetamine) AND (enhance OR enhancement OR enhanc-
er* OR enhancing OR cognition-enhancing OR cognitive-
enhanc*)
OR
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helper OR smart fix OR smarts in a bottle OR smart drugs OR
brain doping OR brave new brain OR clever pills OR iq-profin)
AND (enhance OR enhancement OR enhancer* OR enhancing
OR cognition-enhancing OR cognitive-enhanc* OR neuroen-
hance* OR neuro-enhance* OR nootropic* OR cosmetic
neurology OR cosmetic psychopharmacology)
A l la r t i c l e sw e r er e a da n dc h e c k e df o rr e l e v a n c ea c c o r d i n gt o
pre-established inclusion and exclusion criteria. Articles were
only included if they directly discussed neuroenhancement,
which we defined as the use of pharmaceutical drugs to
improve cognitive function in those without a disorder. We
excluded articles whose main focus was the use of stimulants for
therapeutic purposes (e.g. the treatment of ADHD); enhance-
ment use in sport; cosmetic surgery; enhancement using natural
remedies; drug misuse that was not for enhancement purposes;
and articles of less than 50 words; book reviews; and, duplicate
articles. When articles were rep r i n t e di ns h o r t e ra n dl o n g e r
forms both versions were considered as distinct and separate,
a n di n c l u d e di nt h ea n a l y s i s .At o t a lo f1 4 2a r t i c l e sw e r e
included in the analysis.
Analysis
Phase 1: Prevalence of neuroenhancement
Two members of the research team (BP and JL) independently
classified each media article according to its overall portrayal of
the prevalence of neuroenhancement using the following catego-
ries:
1) Neuroenhancement is common, widespread or high in
prevalence (an excerpt indicative of this category was ‘‘The
survey focused on Ritalin and Modafinil. Both medications are common
on college campuses as study aids’’);
2) Uncommon or low prevalence (for example ‘‘There has always
been a small but determined minority...’’);
3) Unknown prevalence (an indicative description being ‘‘No
one knows how many people are using modafinil off- label as a cognitive
enhancer to improve their thinking ability’’);
4) Neuroenhancement is increasing in prevalence (an indica-
tive description being ‘‘Students are increasingly taking drugs like
Ritalin instead of Red Bull or triple espressos’’);
5) No mention of the prevalence.
Early in the analysis we found that some articles described
neuroenhancement as both ‘‘common’’ and ‘‘increasing’’ so we
amended the classification structure to note these examples. After
separately classifying each article, the initial agreement rate
between the two researchers was 82% (116/142 articles). The
two raters met to discuss the remaining 26 articles and reached a
consensus on the rating.
Phase 2: Evidence cited for prevalence
Each article in the sample was then examined by two members
of the research team (BP and SB) to identify the type of evidence
that was used to support claims about the prevalence of
neuroenhancement. For each article, SB used NVivo 9 to code
each portion of text that described the prevalence of neuroen-
hancement. Coded text ranged from individual sentences to entire
paragraphs. Some articles made several separate claims about the
prevalence of neuroenhancement whereas other articles made only
one claim. Each claim was classified according to the evidence
cited:
1) Anecdotal evidence (e.g. ‘‘Michael, 23, said about a quarter of his
postgraduate classmates were taking amphetamine-based stimulants to
enhance their ability to study’’);
2) Academic research/studies/papers;
3) Scientist or researcher opinion/quotation;
4) Other expert opinion/quotation (e.g. physicians, university
representatives);
5) No evidence.
SB and BP then reached consensus on any items that were
unclear. At this point the coding structure was refined to more
accurately describe how the media articles referred to ‘‘academic
research/studies/papers’’. Some media articles referred to specific
surveys or papers from the academic literature either by naming
the author(s) or journal (e.g. it was clear that the following referred
to the Nature paper by Maher, 2008: ‘‘The scientific journal Nature
published the results of an online survey of 1,400 adults. It showed that 20%
of readers had taken "smart drugs"). Other media articles referred only
to unnamed ‘‘research’’ or ‘‘studies’’ (e.g. ‘‘One in six university
students uses ’smart drugs’, studies in the US show’’). We separated this
code into:
1) Named academic research/ studies/papers (either by naming
the journal or author)
2) Unspecified research/studies/papers.
BP then separately coded the portion of text in each article that
referred to the prevalence of neuroenhancement as: 1) anecdotal
evidence; 2) named academic research/studies/papers; 3) unspec-
ified research/studies/papers; 4) scientist or researcher opinion/
quotation; 5) other expert opinion/quotation (e.g. physicians,
university representatives); 6) no evidence.
Phase 3: Benefits of using prescription drugs for
neuroenhancement
BP and SB conducted a thematic content analysis of the possible
benefits of prescription drugs for neuroenhancement mentioned in
each media article. Categories were initially derived from the most
commonly noted benefits in the academic literature, and other
benefits emerged during the coding process (e.g. improved
attention, concentration, alertness, and memory; enhanced ability
to study; improved exam performance/better grades; increase
intelligence; help to stay awake/reduce fatigue; relieve jet-lag;
improve learning; work faster/be more productive). Coded text
claimed that prescription drugs have benefits for healthy people
(for example the following sentence was coded as ‘‘improve
memory’’ and ‘‘improve attention’’: ‘‘[Ritalin] is also effective in the
healthy brain, where it improves memory and the ability to focus attention’’), or
claimed that healthy people use them to achieve certain benefits
(for example the following sentence was coded as ‘‘improve
concentration’’: ‘‘The majority of these med-taking brainiacs said they
indulged in order to improve concentration). We also coded text that cited
self-reported or purported/possible benefits, for example the
following excerpt was coded as ‘‘improve exam performance/
better grades’’ and ‘‘improve concentration’’:
Matt, a business finance student at the University of Florida, claimed a
similar drug, Adderall, had helped him improve his grades. "It’s a miracle
drug," he told The Boston Globe. "It is unbelievable how my concentration
boosts when I use it."
During the coding process, we found that a number of articles
mentioned non-specific cognitive benefits of using prescription
drugs that could be described as an improvement in brain or
mental functioning, for example the potential to ‘‘fine-tune mental
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record these instances of general, non-specific cognitive benefits.
We aggregated the number of media articles in the sample that
mentioned each benefit.
Phase 4: Risks and side effects
BP and SB conducted the same type of thematic content
analysis for the health risks/side-effects of using prescription drugs
for neuroenhancement. Categories were derived from the most
commonly mentioned risks/side-effects in the literature for
example, insomnia; the potential for addiction/dependence;
abuse; mental health problems including anxiety; headache; heart
problems; loss of appetite/nausea. Other risks were allowed to
emerge from the data. During the coding process we created a new
category for texts that mentioned the possibility of non-specific
risks, side effects, or dangers for example: ‘‘drugs, especially when they
are not used as intended, can have dangerous side effects. Cerebral candy should
not be sold out of gumball machines’’. We also recorded the number of
articles that did not mention any specific or non-specific risks, side-
effects or dangers. We then aggregated the number of media
articles in the sample that mentioned each risk.
Results
1) Prevalence of neuroenhancement
Eighty-seven percent of media articles (124/142) made some
mention of the prevalence of neuroenhancement. The other 18
focused solely on other issues. The overwhelming majority of the
former (94%, 116/124) described neuroenhancement as common,
increasing in prevalence, or both (see Table 1).
Only 6 articles said that neuroenhancement was uncommon
and 2 articles said that the prevalence was unclear because of a
lack of empirical evidence or study limitations, for example:
Volkow says no one knows how many people are using modafinil off- label
as a "cognitive enhancer" to improve their thinking ability and work for hours
on end. "It’s not like anyone has done a proper survey to actually document
that," Volkow says.
Media articles varied in the number of claims they made about
the prevalence of neuroenhancement – while some made only one
claim, others made three or more. 10 articles that said
neuroenhancement was common also included a ‘‘counter view’’
– that is, a statement that queried the claims made in the rest of
the article without representing the dominant view in the article.
These counter views (low=6, and unclear prevalence=4) were
presented as opinion, cursorily mentioned; they were not
expressed strongly enough to change the overall impression
created by the article that neuroenhancement stimulant use was
common.
Neuroenhancement is common and increasing. Ninety-
three articles portrayed neuroenhancement as common. They
said, for example, that ‘‘many students’’ use stimulants to improve
their academic performance, that it is ‘‘popular’’, ‘‘commonplace’’,
‘‘widespread’’, or even ‘‘rife’’. The high prevalence of neuroenhance-
ment was sometimes reflected in article titles such as ‘‘Poll finds most
take ’smart drugs’ to help with studies’’;‘ ‘ One in five admit using brain
drugs’’; and, ‘‘Student ‘dex’ rife’’. An article titled ‘‘Brainiac drug use at
work’’ claimed that:
[Ritalin and Provigil] are common currency on US college campuses,
used as ‘study aids’ to sharpen performance and wakefulness.
Another theme was that these drugs were being used on a
regular basis, for example:
Ashley is one of thousands of students who regularly turn to cognitive-
enhancing drugs to improve their mental alertness and performance.
The paradigm use of prescription stimulants was as a ‘‘study aid’’
by university students but widespread neuroenhancement was also
reported among academics and scientists, military personnel, shift
workers, doctors and other ‘‘high-flying professionals’’. One article
titled ‘‘They call it the professional’s pill’’, said that the use of smart
drugs is ‘‘spreading across all sectors of society’’.
Seventy-seven media articles portrayed the phenomenon as
increasing in prevalence. It was, for example, said to be engaged in
by ‘‘more and more students worldwide’’, had ‘‘proliferated in recent years’’,
use had ‘‘soared’’, and that ‘‘students are increasingly taking drugs like
Ritalin instead of Red Bull or triple espressos’’. Some predicted that this
trajectory of use would make drugs for neuroenhancement "as
common as coffee within a decade or two’’. Other articles reported that
the demand for cognitive enhancing drugs had created a ‘‘booming
internet black market’’.
2) Evidence cited for the prevalence of
neuroenhancement
Media articles typically cited several main sources of evidence
for the view that neuroenhancement was common and increasing
(see Table 2). Forty articles (33%) included at least one claim about
the prevalence of neuroenhancement without referring to any
specific evidence for that claim, for example ‘‘Increasing numbers of
stressed students are taking ’smart pills’ to boost exam performance’’.
Nineteen articles (15%) included at least one claim that was based
on anecdotal reports of widespread use, for example:
‘‘This stuff is being passed around all the time,’’ says one male A-level
student with something of a smart-drug habit – ‘this stuff’ largely being
Ritalin.
Unspecified research. Eighty-two (66%) articles made at
least one claim that referred to research. Forty-five articles (36%)
did not give specific details about the author(s) or the journal in
which it was published, simply referring to ‘‘experts’’, ‘‘scientists’’,
‘‘studies’’ or ‘‘research’’. Thirty of these articles offered a
prevalence rate from unspecified surveys or studies but the specific
figures cited point to the probable source for some of them. These
examples over-extended the findings, or reported an outlying
finding from a single study. Nine articles suggested that ‘‘16%’’ of
students use drugs for neuroenhancement, for example:
Surveys in the United States indicate that 16% of university students are
using "smart drugs".
These media articles are most likely referring to a study by
Babcock and Byrne [23] that has often been mistakenly cited in
leading articles in the bioethics literature as evidence that
neuroenhancement is widespread (for examples see [17]). Babcock
and Byrne in fact reported that 16.6% of students in one liberal arts
college had used Ritalin for fun at least once in their lives [23].
Table 1. Media portrayal of the prevalence of
neuroenhancement.
DESCRIPTION OF PREVALENCE TOTAL
Common, widespread or high prevalence & Increasing in
prevalence
54
a
Common, widespread or high prevalence 39
Increasing in prevalence 23
Did not mention prevalence 18
Low prevalence or uncommon 6
Prevalence is unknown 2
a10 articles also included one ‘‘counter view’’ (6= low prevalence; 4=
unknown).
doi:10.1371/journal.pone.0028416.t001
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scientific studies more accurately but nonetheless exaggerated the
prevalence of cognitive enhancement. For example:
...prescription-only drugs are already increasingly being used to enhance
memory, attention span and wakefulness. Studies show that up to a quarter of
students at some U.S. universities have used them in the past year...
The 15 media articles that mentioned a prevalence rate of 25%
probably referred to McCabe et al.’s [24] study of non-medical use
of prescription stimulants in 119 US colleges (which has also been
widely cited in same leading bioethics articles for example Greely
et al. [11]). In that study, one college out of 119 reported that 25%
of students had used stimulants in the past year. The more
representative rate of use in the past year for the whole 119
colleges was only 3% (the median). Only five articles mentioned
the past year or lifetime prevalence rate in that study (4–7%) in
addition to the 25% outlier.
Specified papers from the literature. The academic
sources that the media cited as evidence for the prevalence of
neuroenhancement were written by bioethicists or neuroscientists;
they were rarely primary surveys of the prevalence of neuroen-
hancement. The most highly cited of these articles were an online poll
inNature byMaher[14] titled ‘‘Pollresults:look who’sdoping’’. This
paper was mentioned by 28 media articles; a commentary in Nature
by Sahakian and Morein-Zamir [6] titled ‘‘Professor’s little helper’’,
mentioned by 7 articles; a commentary in Nature by Greely et al.
[11] (6 articles); a commentary in Journal of Medical Ethics by Cakic
[13] (5 articles), a report by the Academy of Medical Sciences [25]
(5 articles); a report by the British Medical Association [26] (3
articles); and a study by Prudhomme White et al. [27] (2 articles).
A typical media reference to the Nature poll by Maher [14] was
as follows:
A poll by scientific journal Nature found one in five respondents said they
took drugs such as Ritalin, and most of the 1400 respondents said adults
should be allowed to use them.
In some cases these poll results were misinterpreted as applying
to all scientists, for example:
One-fifth of the world’s professional scientists and university science
students have used "cognition-enhancing" prescription drugs to help them
concentrate...
Lay readers are unlikely to appreciate that a self-selected group
of participants in an online poll are not representative of the
‘‘world’s professional scientists’’. A typical media reference to the
Nature article by Sahakian and Morein-Zamir [6] was:
[Stimulants] are popular among academics, students and workers looking for
a brain boost. "Off-label and nonprescription use by the general public is
becoming increasingly commonplace" Cambridge University researchers reported
in the science journal Nature.
A typical reference to Greely et al.[11] was:
A group of experts is arguing, in an essay in the prestigious scientific journal
"Nature," that we should acknowledge the fact that a growing number of
healthy college students and adults are using mind-enhancing drugs to improve
their performance.
The articles by Greely et al.[11], Sahakian and Morein-Zamir
[6], and Cakic [13] focused largely on ethical issues raised by
cognitive enhancement. They did not report primary research or
comprehensively review the literature although they did claim that
neuroenhancement is widespread or increasing. One media report
misreported Cakic [13] as primary evidence that:
Research from the University of Sydney has warned that students are
increasingly using` `performance enhancing’’ psychostimulants usually prescribed
for Alzheimer’s, Parkinson’s or sleep disorders, to enhance their academic
performance.
Researcher/expert opinion. A small number of articles
quoted experts such as university spokespeople, student represen-
tatives, or health professionals (n=9). Twenty-three articles
reported the opinion of academic researchers on the prevalence
of cognitive enhancement, but only Sahakian (n=9) and Cakic
(n=8) were quoted by more than one article. For example, one
article said:
Vince Cakic, a researcher from the University of Sydney’s school of
psychology, said students were increasingly using psychostimulants — drugs
usually prescribed for neuropsychiatric disorders and sleep disorders — to
enhance their academic performance.
One media article reported anecdotal evidence cited by
Sahakian as evidence that many academics use modafinil to
enhance productivity, for example:
Professor Sahakian said. "I went to a meeting in Florida and I said to a
colleague ’I’m suffering from jetlag’, and he said to me ’would you like some of
my modafinil?’ A lot of my colleagues (are) using it."
An evidential circle. We found one interesting interaction
between media and academia portrayals of the prevalence of
neuroenhancement. In early 2009, the Cambridge student
newspaper Varsity ran several articles about the use of ‘‘smart
drugs’’ by students and academics. It then conducted its own
survey of 1000 Cambridge students and reported that ‘‘One in ten
takes drugs to study’’ without prescription. This poll was then
reported in 3 media articles in our sample, for instance:
A recent survey of 1,000 Cambridge undergraduates showed that one in 10
had used cognitive-enhancing drugs - also known as "professor’s little helpers".
Another third said they would use them if they had access to them.
This excerpt did not indicate that the survey of Cambridge
undergraduates was an informal poll conducted by a student
newspaper, rather than a scientific survey published in the peer-
Table 2. Evidence cited by media articles for claims about the
prevalence of neuroenhancement.
EVIDENCE CITED
TOTAL
a
n=124(%)
b
No evidence cited for claim 40 (33%)
c
Anecdotal evidence 19 (15%)
Academic research/study/paper 82 (66%)
Named research/study/paper 55 (44%)
Maher (2008) 28 (23%)
Sahakian & Morein-Zamir (2007) 7 (6%)
Greely et al. (2008) 6 (5%)
Cakic (2009) 5 (4%)
Academy of Medical Sciences (2008) 5 (4%)
British Medical Association (2007) 3 (2%)
White et al. (2006) 2 (2%)
Other papers 4 (3%)
Unspecified research/study/paper 45 (36%)
Researcher opinion 23 (19%)
Sahakian 9 (7%)
Cakic 8 (6%)
Other researcher 6 (5%)
Other opinion 9 (7%)
athe total sample minus those articles that did not mention the prevalence of
neuroenhancement.
bpercentages are not cumulative because more than one source of evidence
may be cited in each article.
cpercentages have been rounded to the nearest whole number.
doi:10.1371/journal.pone.0028416.t002
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text (especially given the reference to Cambridge). The results of
the Varsity poll have since been cited in the scientific literature [28]
as evidence that cognitive enhancement use of stimulants is
widespread.
3) Benefits of healthy people using prescription drugs for
neuroenhancement
Ninety-five percent of articles listed at least one potential
neuroenhancing benefit of using methylphenidate, dexamphet-
amine or modafinil. The most commonly mentioned were a
general improvement in brain or mental functioning (for example
‘‘improve mental prowess’’; ‘‘boost brain power’’); improved concentra-
tion; better grades or improved exam/academic performance;
improved memory; stay awake/reduce fatigue; increased alertness;
and use to help study (see Table 3).
These media articles either asserted that these drugs produced
the benefits that were mentioned (e.g. ‘‘[Ritalin] is also effective in the
healthy brain, where it improves memory and the ability to focus attention’’),
mentioned their possible benefits without questioning their
efficacy, or implied their efficacy (e.g. ‘‘Writing in the journal Nature,
the academics argue that the prescription- only drugs are already increasingly
being used to enhance memory, attention span and wakefulness.’’).
Twenty-two articles (15%) expressed some doubts about or
questioned the enhancement efficacy of prescription drugs, for
example:
...proper studies on the use of enhancers in healthy people may well show a
significant placebo effect, where people take a pill and then make sure they do
the work. "There is considerable individual variation," he [Dr. Sandberg]
said.
4) Risks of using prescription drugs for
neuroenhancement
58% of articles mentioned at least one possible health risk/side-
effect of using prescription drugs for neuroenhancement (see
Table 4). Most often the risks were unspecified (n=44, 31%) for
example:
She [Barbara Sahakian] warns against the potential dangers of people under
20, whose brains are still developing, taking smart drugs like Ritalin unless
they have a condition such as ADHD.
33/44 articles that mentioned general risks or dangers also
mentioned at least one specific risk. For example, the above-
mentioned article went on to say that there is also ‘‘a potential for
abuse’’. The most commonly mentioned specific risks/side-effects
in the sample were mental health problems; addiction/dependen-
cy; heart or blood pressure problems; insomnia; headache; abuse;
loss of appetite or nausea; and death.
Discussion
Our analysis indicates that most newspaper articles portray
neuroenhancement as common or increasing in prevalence. Very
few portrayed it as rare or of unknown prevalence. This is despite
the largest and most representative surveys to date suggesting a
past year prevalence of nonmedical stimulant use of 3–6% [17,18].
Two-thirds of media articles referred to the academic literature in
some way to support claims that neuroenhancement is common or
increasing and 44% either named an author or a journal. The
Nature poll by Maher [14] was the most cited paper about
prevalence even though this reported an informal poll of self-
selected readers that was unlikely to be representative of the
journal’s readership or the world’s scientists. Sahakian & Morein-
Zamir [6]; Greely et al. [11]; and Cakic [13], were the next most
cited papers about prevalence. These were commentaries on the
ethics of neuroenhancement that also claimed neuroenhancement
was widespread or increasing. However they sometimes cited
research in ways that misinterpreted the prevalence of neuroen-
hancement (see [17]).
When media articles cited prevalence estimates from the
academic literature they often misinterpreted the data (e.g.
Table 3. Benefits of using prescription drugs for
neuroenhancement mentioned in print media.
BENEFITS
TOTAL
n=142(%)
ab
No benefits mentioned 7 (5%)
Improve brain/mental function 59 (42%)
Improve concentration 57 (40%)
Better exam/academic performance, or better grades 55 (39%)
Improve memory 44 (31%)
Stay awake/reduce fatigue 43 (30%)
Increase alertness 34 (24%)
Help study 30 (21%)
Improve attention 23 (16%)
Efficacy of drugs for CE is uncertain 22 (15%)
Work faster/more productive 17 (12%)
Relieve jet-lag 17 (12%)
Increase intelligence 13 (9%)
Better than caffeine 10 (7%)
Enhance learning 9 (6%)
Increase motivation 8 (6%)
apercentages are not cumulative because more than one benefit may be cited
by each media article.
bpercentages have been rounded to the nearest whole number.
doi:10.1371/journal.pone.0028416.t003
Table 4. Risks/side-effects of using prescription drugs for
neuroenhancement mentioned in print media.
RISKS/SIDE EFFECTS
TOTAL
n=142(%)
ab
No risks/side effects mentioned 60 (42%)
Unspecified risks/side effects 44 (31%)
Mental health problems (inc. anxiety and depression) 27 (19%)
Addiction/dependency 22 (15%)
Heart or blood pressure problems 22 (15%)
Insomnia 20 (14%)
Little is known about the risks 20 (14%)
Headache 19 (13%)
Abuse 17 (12%)
Loss of appetite or nausea 16 (11%)
May be fatal 10 (7%)
apercentages are not cumulative because more than one risk/side-effect may be
cited by each media article.
bpercentages have been rounded to the nearest whole number.
doi:10.1371/journal.pone.0028416.t004
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readers indicated they had used drugs for cognitive enhancement
as showing that ‘‘20% of the world’s scientists’’). They also presented
data in ways that amplified the prevalence of neuroenhancement
(e.g. by highlighting the minority of studies with higher estimated
prevalence of use between 16–35%). They also failed to report
important qualifications on the data (e.g. small samples from single
colleges).
Interestingly, a recent review of the evidence for the prevalence
of neuroenhancement alluded to increased media attention,
saying ‘‘To judge from recent reports in the popular media, healthy people
have also begun to use MPH and AMPs for cognitive enhancement’’ [18]. It
went on to say that a number of major newspapers and other
popular media ‘‘have reported a trend toward growing use of prescription
stimulants by healthy people for the purpose of enhancing school or work
performance’’ [18]. Our results indicate that the main source for
media claims that neuroenhancement is common and increas-
ingly widespread has been enthusiastic reports from the academic
literature. As Bubela and Caulfield [3] suggest, journalists are not
always the sole source of exaggerated claims about science. As
with the creation of ‘‘genohype’’, neuroscientists and bioethicists
have contributed to the creation of a ‘‘bubble of enthusiasm’’ for
neuroenhancement.
Media articles also provided positive statements about the
enhancement benefits of using these drugs. Nearly all articles in
our study (95%) mentioned at least one possible benefit of using
prescription drugs for neuroenhancement, but only 58% men-
tioned any risks/side effects. Only a minority of articles expressed
doubts about or questioned the evidence for efficacy of
prescription drugs to produce benefits to users – this is despite
recent reviews indicating only modest evidence for their cognitive
enhancing effects [22]. This is in line with other studies showing
that the media often under-reports risks whilst emphasising the
potential benefits of both neuroscience innovations [1] and
prescription medication [29,30].
These findings have several implications of concern. Firstly,
misleading media reporting increases the likelihood that public
policy with be poorly informed. If neuroenhancers are believed to
be widespread and effective for improving concentration or getting
better grades, then policies may mistakenly be developed to
facilitate such use. In the bioethics literature, these claims have
promoted recommendations to: make it legal for students to use
psychostimulants for neuroenhancement without a prescription;
allow pharmaceutical companies to market these drugs to healthy
people for neuroenhancement; and ensure that these drugs are
available to all students so that none miss out on the advantages
that they provide [11]. For example, the American Academy of
Neurology has suggested that it is morally and legally acceptable
for neurologists to prescribe these drugs to healthy people for the
purposes on neuroenhancement [7]. Other authors have specu-
lated about the implementation of ‘‘drug-testing’’ students before
exams to avoid what is seen as ‘‘cheating’’ [13].
A second concern is about the possible impact of media
reporting of neuroenhancement on reader behaviour. Forlini and
Racine [31] found that healthcare providers, students and parents
all viewed the media as an important source of information about
neuroenhancement. Their interviewees were concerned that
unbalanced reporting could unwittingly normalise this behaviour.
More research is required to explore this potential effect of media
coverage but there was some suggestive evidence of an effect in
several media articles in our sample. These reported the views of
students who implied that media reports provided the initial
impetus to experiment with purported neuroenhancers. For
example:
"I read an article in the student press on them," says Lawrence Price, a
third-year arts student at Sheffield Hallam University. "It was criticising them,
but I thought they sounded great." Perera, similarly, found out about smart
drugs through the media. "I read an article in Nature on them," he says. "They
seemed a pretty good idea."
We found that even though many newspaper articles mentioned
the potential risks, most nevertheless pointed out many possible
benefits. The benefits of neuroenhancement clearly stood out to
the first student quoted above, even in an article that was
apparently critical of the practice.
One possibility worth discussing is the potential role of media
guidelines on responsible reporting of drug use. The Australian
Press Council, for example, has guidelines on the responsible
media coverage of illicit drug use. This limits details of reporting
about the quantity, methods of administration and drug
composition in an attempt to limit unintended, indirect encour-
agement of drug use [10]. These guidelines could be adapted to
reporting of nonmedical use of prescription drugs for any purpose,
including neuroenhancement. Reporters should be encouraged to
cite high quality evidence (i.e. well conducted primary research
studies) as the basis for claims of prevalence. They should avoid
overstating benefits in ways that may encourage use.
We did not assess whether all the articles in our sample would
comply with these guidelines but articles that overstate the
prevalence, efficacy, and benefits of prescription drugs for
neuroenhancement and not giving equal consideration to their
risks arguably encourage readers to try these drugs. We found a
small number of media articles that described journalists’ own
experimentation with prescription drugs as neuroenhancers. For
example, one article described how to obtain modafinil:
Finally, I tried a randomly picked doctor. Fortunately, his standards weren’t
as high as my friend’s, and he gave me a prescription for a £5 ’admin fee’.
The journalist went on to describe the neuroenhancement benefits
he experienced from several 100 mg and 200 mg doses, as well as
other unexpected benefits such as ‘‘being the life of the party’’:
Concentration and output sky-rocketed and I felt fantastic. In fact, during
my two weeks of Modafinil-enhanced life I did tons of good work, gained two
new regular slots in newspapers, lost 4lb in weight and cleared an Augean
stable of admin. But I’m not sure Modafinil really increases your memory or
makes you more intelligent. It makes you think you’re more intelligent.
The next morning, I had a horrendous hangover but was cheered by reports
from my girlfriend, who said her friends thought I was the life and soul of the
party. Was that a euphemism for loudmouth buffoon, I asked? ’No, really, you
were fun’, she insisted.
Limitations
Our findings should be interpreted with the following
limitations in mind. Firstly, the generation of our media sample
relied upon a search strategy consisting of key terms related to
cognitive enhancement. However, the broadness of terminology
used in neuroenhancement discussions also means that there may
be media articles that our search terms did not capture (‘‘false
negatives’’) that other search strategies may [32]. Secondly, our
search strategy focused on news print media articles given that
they are the most widely circulated form of print media catering to
a broad, lay readership. It would be worthwhile for future
investigations to explore other media such as television, magazines,
radio, film, or internet blogs. Thirdly, our sample was limited to
English language articles (primarily from the USA, UK and
Australia) listed in the Factiva database.
Conclusions
While it is easy for researchers to blame the media for
misrepresenting their research, researchers also have an ethical
Media and Neuroenhancement
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least amenable to such misrepresentation. Poor reporting, citation
and translation of data all increase the potential for research to be
inaccurately interpreted by other researchers and by the media
[4,33]. When important pieces of information that qualify or
contextualise the results are omitted, research findings can be
seriously misrepresented, as we argue has happened in the case of
putative neuroenhancement use of prescribed stimulant drugs.
Neuroscience and bioethics researchers, and science journal
editors, have an obligation to ensure that they do not contribute
to uncritical media portrayals that inflate the prevalence of
cognitive enhancement, as our data suggests some have done to
date.
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